HAE in the News

The articles listed below are various press releases on Hereditary Angioedema

---

Page#:  1  2  3  4  5  6  7  8  9  10 


Unexplained Acute GI Pain Could be Hereditary Angioedema
Severe acute abdominal pain, which may recur with no obvious clinical explanation, could be due to hereditary angioedema, reported investigators here. ...more


Study Shows Undiagnosed Hereditary Angioedema Can Lead to Unnecessary Surgeries, Testing in Patients with Abdominal Pain
A chart review conducted by researchers at the Institute for Asthma and Allergy showed that hereditary angioedema (HAE) patients who present only with recurrent severe abdominal pain frequently undergo unnecessary surgeries and diagnostic tests ...more


Jerini AG (DE) - Ad hoc: Jerini Plans to Submit US New Drug Application in Third ...
Jerini AG (FSE:JI4) announced today, following a pre-NDA meeting with the United States Food and Drug Administration (FDA), its plans to submit a New Drug Application (NDA) for Icatibant in the treatment of hereditary angioedema (HAE) in the third quarter 2007. ...more


Dyax and Genzyme Announce Agreement to Terminate Joint Venture for the Commercialization of DX-88 in HAE
Dyax Corp. (NASDAQ: DYAX - News) announced today that it has reached a mutual agreement with Genzyme Corporation (NASDAQ: GENZ - News) to terminate their joint venture for the development and commercialization of DX-88 for hereditary angioedema (HAE). ...more


Lev Pharmaceuticals Announces Final Patient Treated in Pivotal Phase III HAE Trial
Lev Pharmaceuticals, Inc. (Lev) (BULLETIN BOARD: LEVP.OB) , ..., announced today that it has completed patient treatment in the acute portion of a pivotal Phase III clinical trial for its lead product candidate, C1-esterase inhibitor ...more


Dyax Corp. Issued Two Patents for Use of DX-88 in CTS
Dyax Corp. (Nasdaq:DYAX) announced today that the United States Patent and Trademark office has issued two U.S. Patents relating to its program for on-pump cardiothoracic surgery (CTS). U.S. Patent No. 7,153,829 (issued December 26, 2006) covers methods for preventing or reducing perioperative blood loss due to surgery by administering its proprietary kallikrein inhibitor, DX-88 (ecallantide), as well as methods for preventing or reducing reperfusion injury with DX-88. ...more


Affliction of a few
Drug companies are slow to develop cures for rare, often deadly diseases because of small patient lists ...more


New Hope For Suffers Of Rare Disease
A rare disease is getting special attention in Tulsa. It's called hereditary angioedema, and fewer than 10,000 Americans have the disease. But News on 6 anchor Terry Hood says for people in a new study, an experimental drug is finally spelling relief. ...more


Sudden Swelling Can Be Life-Threatening To Some
All parents worry about bee stings and spider bites because of the swelling and pain they cause, but you also need to know about sudden swelling that has no cause. It can happen at any age and can be life-threatening ...more


Dyax Announces Final Patient Treated in Pivotal Phase III Clinical Trial (EDEMA3) for DX-88 in Hereditary Angioedema
Dyax Corp. (Nasdaq:DYAX) announced today that it has completed the double-blind portion of its pivotal Phase III clinical trial, known as EDEMA3, for its lead product candidate DX-88 (ecallantide) for the treatment of hereditary angioedema (HAE). ...more


Page #:  1  2  3  4  5  6  7  8  9  10 

The US Hereditary Angioedema Assoc., Seven Waterfront Plaza, 500 Ala Moana Blvd., Suite 400, Honolulu, HI 96813, (866) 798-5598

The US HAEA's 2010 corporate sponsors